Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Charting Its Own Course in Psychedelic Space

Rhea-AI Summary

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announced its inclusion in an editorial by NetworkNewsWire, highlighting the potential of psychedelics in the therapeutic landscape. The article drew parallels between Tryp and GW Pharma, noting Tryp's focus on developing psilocybin-based treatments for neuropsychiatric disorders, including fibromyalgia and eating disorders. The company is preparing for a phase 2a clinical study in partnership with the University of Florida. Tryp continues to pursue innovative treatments for rare diseases, emphasizing its unique position in the burgeoning psychedelics market.

Positive

• Tryp is developing psilocybin-based treatments, which have significant therapeutic potential.
• The company is initiating a phase 2a clinical study for eating disorders in collaboration with the University of Florida.
• Management team demonstrates a successful track record in drug development.

Negative

• None.

News Market Reaction – TRYPF

+4.36%

1 alert

+4.36% News Effect

On the day this news was published, TRYPF gained 4.36%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

To view the full publication, “GW Pharma Sells for Bilions; Psychedelic Company Following Similar Path,” please visit: https://nnw.fm/0N5t5

In May 2013, GW Pharma listed on Nasdaq, selling 3.5 million shares at $8.90 each to investors betting that GW was charting a profitable course as a biotech developing new drugs from cannabis-derived compounds. Legal cannabis was only beginning to gain momentum at that time, and while countless companies saturated the market as would-be growers, distributors, etc., GW was taking a more difficult route of drug development with much greater upside if successful. The strategy paid off as the company received FDA approval for the first-ever cannabis-based drug in June 2018.

There are some notable similarities between the evolution of the legal cannabis market a decade ago and the current status of psychedelics, longtime illicit drugs that are now being evaluated for their therapeutic potential by a handful of upstart companies. San Diego-based Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) stands out, not only for its still-small valuation but also because it has a successful management team that, much like GW, is charting its own course in the space.

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and safety profiles for the treatment of rare and other diseases with unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than five million people in the United States. The company is also preparing to initiate a phase 2a clinical study for eating disorders in partnership with the Dr. Jennifer Miller at the University of Florida. In addition to its PFN program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft-tissue sarcoma. Soft-tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft-tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for orphan drug status.

For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYP are available in the company’s newsroom at https://ibn.fm/TRYPF.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness.

NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only).

For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website, applicable to all content provided by NNW wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

FAQ

What is Tryp Therapeutics' focus in drug development?

Tryp Therapeutics focuses on developing compounds with known activity for treating neuropsychiatric disorders and other rare diseases.

What clinical study is Tryp Therapeutics preparing to initiate?

Tryp Therapeutics is preparing to initiate a phase 2a clinical study for eating disorders in partnership with the University of Florida.

What are the potential treatments being developed by Tryp Therapeutics?

Tryp is developing psilocybin as a new class of drug for treating fibromyalgia and other neuropsychiatric disorders.

How does Tryp Therapeutics compare to GW Pharma according to the recent editorial?

The editorial compares Tryp to GW Pharma by highlighting similar market conditions and innovative drug development strategies.